Victoza Clears European Regulators Without Thyroid Cancer Restrictions
Executive Summary
NovoNordisk is facing a much easier path for Victoza (liraglutide) in Europe than the rocky road the type 2 diabetes therapy is on in the U.S
You may also be interested in...
FDA Clears Victoza, But Warnings And More Studies Pose Hurdles
That FDA's approval of Novo Nordisk's Victoza (liraglutide) uses its full cadre of FDA Amendments Act-granted drug safety controls - a Risk Evaluation and Mitigation Strategy and mandatory post-marketing requirements - is not surprising, given the concern about a potential cancer risk. But it is a disappointment to investors
FDA Clears Victoza, But Warnings And More Studies Pose Hurdles
That FDA's approval of Novo Nordisk's Victoza (liraglutide) uses its full cadre of FDA Amendments Act-granted drug safety controls - a Risk Evaluation and Mitigation Strategy and mandatory post-marketing requirements - is not surprising, given the concern about a potential cancer risk. But it is a disappointment to investors
FDA Clears Victoza, But Warnings And More Studies Pose Hurdles
Liraglutide's US approval comes with a black box warning for a thyroid cancer risk and hefty post-marketing requirements.